Close Menu

financial guidance

The company said Q4 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.

The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.

More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.

The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.

Test volumes, revenues per test and costs per test improved during the quarter, the company said.

Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.

Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.

For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.

The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.

Pages

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.